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Original articleFirst experience with sildenafil after Fontan operation:
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Raffaele Giordano, Gaetano Palma, Vincenzo Poli, Sergio Palumbo,
Veronica Russolillo, Sabato Cioffi, Marco Mucerino, Vito Antonio Mannacio and
Carlo VosaBackground We conducted a retrospective study to
determine the effect of oral sildenafil administrated as
monotherapy after Fontan operation in single ventricle
physiology.
Methods From January 2008 to March 2012, during two
different periods, a total of 30 pediatric patients undergoing
Fontan operation by extracardiac conduit were included in
this study. Thirteen patients were in the sildenafil group and
exclusively treated with sildenafil given at the dose of
0.35mg/kg through a nasogastric tube and then orally every
4h, at the start of cardiopulmonary bypass and for the first
postoperative week; then we reduced and discontinued the
therapy. The other 17 patients were in the control group. No
other vasodilator was administered in both groups. We
analyzed intraoperative and postoperative outcomes of
sildenafil administration.
Results There were no differences in mortality or operative
time. The total and relative drainage loss was lower in the
sildenafil group (PU0.0003 and 0.0045). The hemodynamic
parameters showed a better condition in the sildenafil
group, with a lower mean pulmonary artery pressure
(mPAP) (PU0.0001) and better mPAP to mean systemic Copyright © 2015 Wolters Kluwer
1558-2027 Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.blood pressure (mSBP) ratio (PU0.0043), whereas
there was no difference in peripheral oxygen
saturation (PU0.31). The sidenafil group patients
showed other additional positive differences as well
as lower inotropic score (PU0.0005) and intubation
time (PU0.0004). No complications related to the
use of sildenafil were noted in any of the children
studied.
Conclusion This initial experience provides evidence that
sildenafil may be used in postoperative Fontan operation
with positive effectiveness.
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Although the use of sildenafil has become a standard
therapy for adults with pulmonary hypertension, clinical
reports pertaining to the use of oral sildenafil therapy
(OST) (Viagra; Pfizer laboratory, New York, USA) in the
pediatric population with congenital heart disease (CHD)
have appeared only in recent years.1–3 Because of
the diversity of the hemodynamic features in patients
with CHD, it may be difficult to determine the efficacy of
OST in this patient population.
Sildenafil is a selective phosphodiesterase V (PDE V)
inhibitor.1 PDE V specifically hydrolyzes guanosine 30,50-
cyclic monophosphate (cGMP).
Very important to the success of patients undergoing
Fontan staging is the low pulmonary vascular resistance
(PVR). Persistent pleural effusions, protein-losing
enteropathy, formation of collateral vessels, excessive
cyanosis, and failure to thrive are a few of the compli-
cations in this patient population. The acute use of
nitric oxide and other pulmonary vasodilators has beenreported for single ventricle (patients with Fontan
physiology and low cardiac output associated with high
pulmonary artery pressures).4 However, some patients
become symptomatic months to years after Fontan
surgery, and with continued evidence of failure of
the circulation, they are eventually referred for cardiac
transplantation.
We conducted a retrospective study to determine the
effect of oral sildenafil administrated as monotherapy
after Fontan operation in single ventricle physiology.Material and methods
Patient selection
The data used in this retrospective study were collected
at our center during two different periods. Approval was
gained from the Ethics Committee of the University of
Naples Federico II. The Institutional Review Board had
approved the use of databases for research. All partici-
pants were younger than 18 years of age and each legal Health, Inc. All rights reserved.
DOI:10.2459/JCM.0b013e328361390a
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use of their medical records for research purposes.
Children who were scheduled to undergo Fontan
operation between January 2008 and March 2012 were
considered potentially eligible for inclusion in the
study. Regarding the surgical technique employed for
the Fontan operation, extracardiac conduit connection
between the inferior vena cava and the pulmonary artery
was performed in all patients. No fenestration of Fontan
pathway was performed.
The control group included patients who underwent
surgery between January 2008 and December 2009.
During this period no OST was used. The sildenafil
group included all children undergoing Fontan operation
between January 2010 and March 2012. In this group,
sildenafil was administered at the dose of 0.35mg/kg
through a nasogastric tube and then orally every 4 h.
We started the first dose of treatment at the beginning
of cardiopulmonary bypass (CBP), continuing for the first
postoperative week; then we reduced and discontinued
therapy.
In both groups, preoperative catheterization showed low
pulmonary artery pressure (below 15mmHg) and pulmon-
ary vascular resistance less than 2.5 Wood units.4,5
Perioperative management of patients
All other parameters that may influence the perioperative
management, in particular anesthesia, CPB course and
extubation protocol, were not modified during the two
periods under review. All patients were operated upon by
a surgical team of two surgeons without surgical practice
difference between the two time periods. The following
hemodynamic parameters were measured immediately
after surgery and for a further 72 h: mean pulmonary
artery pressure (mPAP), the ratio of mPAP to mean Copyright © 2015 Wolters Kluwe
Table 1 Demographic and preoperative data between sildenafil and c
Characteristics of patients Sildenafil group (n¼13)
Age (months) 5512
Sex (male) 8 (61%)
Weight (kg) 19.73.1
BSA (m2) 0.770.09
mPAP (mmHg) 12.10.6
mPAP/mSBP 0.220.02
SpO2 (%) 82.51.7
PVR (Wood units) 2.20.2
PCWP (mmHg) 8.90.6
Hemoglobin (g/dl) 15.51.4
Creatinine (mg/dl) 0.60.2
Intracardiac defects
TA 4
Univentricular heart 4
TGVþPSþ strad AVV 0
AVSD unbalanced 4
HLHS 0
AVSD, atrioventricular septal defect; BSA, body surface area; HLHS, hypoplastic left hea
pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resist
AVV, transposition of the great vessels, pulmonary stenosis, straddling atrioventriculasystemic blood pressure (mPAP/mSBP), and peripheral
oxygen saturation (SpO2) were measured every 3 h after
the first administration of OST via invasive systemic
arterial and pulmonary arterial lines. Blood and fluid
loss via drains was defined as the total amount lost
via thoracic drains after surgery until their removal.
We removed thoracic drains when fluid loss was less
more 3ml/kg per day. The anesthesiologists were respon-
sible for intraoperative fluid management. We recorded
the total time of surgery and the CPB.
Postoperatively, patients were transferred to the ICU.
In addition to sildenafil, therapy included administering
1–15mg/kg per min of dopamine or dobutamine (0.05–
0.2mg/kg per min of adrenaline was added, when necess-
ary), 0.075–0.15mg/kg per min of remifentanil, and 0.5–
2mg/kg per min of midazolam for sedation. Controlled
ventilation was instituted in order to attain blood pH
values above 7.45 and PaO2 levels above 100 mmHg.
Postoperative care was undertaken by a team of
intensivists who managed bleeding and blood product
administration according to existing protocols. Packed
red cells were used for transfusion if the hemoglobin fell
below 11 g/dl, although a clear-cut trigger of transfusion
was not defined in this study. Fresh frozen plasma
was used if the hemoglobin was above 11 g/dl and
the patients’ clotting factors were considered based on
the results of coagulation tests. Platelet concentrates
were used in a dose of 1 unit (50ml) per 10 kg, and
5% albumin was used for volume replacement if no active
bleeding was present. We performed a replacement of
losses by thoracic drainage following the replacement/
loss ratio as 1 : 1 for the first 2 days after surgery, 1 : 2 ratio
for the next 3 days, and 1 : 4 ratio up to the removal of
the drainage. Then we recorded the intubation time,
ICU stay, and the inotropic score was calculated
as dopamine mg/kg/min 1þdobutamine mg/kg/minr Health, Inc. All rights reserved.
ontrol group
Control group (n¼17) P value
5914 0.42
10 (59%) 0.82
21.14.1 0.31
0.820.12 0.22
11.80.8 0.27
0.210.04 0.42
84.12.5 0.06
2.10.3 0.30
9.21.0 0.34
15.21.1 0.51
0.70.2 0.18
5 0.62
4 0.52
1 0.58
6 0.57
1 0.58
rt syndrome; mPAP, mean pulmonary artery pressure; mSBP, mean systemic blood
ance; SpO2, peripheral oxygen saturation; TA, tricuspid atresia; TGVþPSþ strad
r valve.
554 Journal of Cardiovascular Medicine 2015, Vol 16 No 81þ epinephrine mg/kg/min 100.6 Diuretics (usually
furosemide 1–2mg/kg per dose, two to four times daily)
were begun on the first postoperative morning or earlier if
the patient was oliguric (less than 1ml/kg per h).
Statistical analyses
Continuous data are presented as meanSD. We com-
pared clinical variables between the two groups by means
of the nonparametric Mann–Whitney U test (for con-
tinuous variables) or the x2 test and Fisher’s exact test
(for categorical variables). A P value below 0.05 was
considered statistically significant. Data were analyzed
by means of Statistica 6.0 software (StatSoft, Inc., Tulsa,
Oklahoma, USA).
Results
In this study we included 30 patients – 13 in the
sildenafil group and 17 in the control group. There
was no difference in demographic and preoperative data
between the sildenafil and the control group (Table 1);
only peripheral oxygen saturation tended to be lower
in the sildenafil group (P¼ 0.06). There was no differ-
ence between the intraoperative and postoperative
parameters (Table 2) for mortality or operative time.
In the control group the total drainage loss (1770 310
vs. 1350 230ml; P¼ 0.0003), the relative drainage
loss (P¼ 0.0045), and persistence time (P¼ 0.0004) were
greater. Required chest tube reinsertion after removal
of the drains was similar in the two groups (2/4; P¼ 0.50).
The hemodynamic parameters showed a better
condition in the sildenafil group, with a lower mPAP
(P¼ 0.0001) and a bettermPAP/mSBP ratio (P¼ 0.0043),
whereas there was no difference in peripheral oxygen
saturation (P¼ 0.31). The sildenafil group had a lower
inotropic score (P¼ 0.0005), intubation time (P¼ 0.0004),
timing for chest drainage removal (P¼ 0.0004), and
ICU stay (P¼ 0.0001). No complications related to
the use of sildenafil were noted in any of the children
studied. Copyright © 2015 Wolters Kluwer
Table 2 Intraoperative and postoperative parameters
Sildenafil group (n¼13)
Mortality (in the first 30 days) 0
Total operation time (min) 35542
CPB time (min) 6713
mPAP (mmHg) (after 72 h) 12.61.1
mPAP/mSBP (after 72 h) 0.200.02
SpO2 (%) (after 72 h) 98.31.5
Total drainage loss (ml) 1350230
Relative drainage loss (ml/kg) 68.511.6
Chest drainage removal (days) 5.91.1
Creatinine (mg/dl) (after 72 h) 0.70.2
Inotropic score 18.54
Fluid balance (in first 72 h) (ml) 19070
Intubation time (h) 15.54
ICU stay (h) 8610
CPB, cardiopulmonary bypass; mPAP, mean pulmonary artery pressure; mSBP, meanDiscussion
Pulmonary circulation plays an important role in
mortality and morbidity after right heart bypass surgery,
including the Fontan-type procedure and bidirectional
cavopulmonary shunt.7,8 Severe impairment of the
pulmonary circulation only occurs infrequently after
right heart bypass surgery, but such impairment causes
increased central venous pressure and decreased left-
heart preload, leading to severe congestion in the major
organs and low cardiac output syndrome, respectively.
There are various options for treatment of impaired
pulmonary circulation, including intravenous trinitrogly-
cerine (TNG), prostaglandin E1, prostacyclin and inhaled
nitric oxide.9 Sildenafil has recently been used to treat
various types of pulmonary hypertension. Sildenafil is
a selective phosphodiesterase-5 (PDE-5) inhibitor, the
predominant PDE isoform responsible for hydrolysis of
guanosine 30,50-cyclicmonophosphate (cGMP) in vascular
smooth muscle cells in the lungs.
Patients who undergo Fontan procedure or bidirectional
cavopulmonary shunt may have a pulmonary vascular
dysfunction,10 with blunted release of endothelium-
derived nitric oxide. This is consequent to the loss of
flow pulsatility in the pulmonary circulation. Pulmonary
endothelial dysfunction might lead to increased pulmon-
ary vascular resistance and attenuation of the physiologic
lowering of pulmonary vascular resistance induced by
nitric oxide release. Administration of the selective
pulmonary vasodilator-inhaled nitric oxide to patients
with Fontan circulation reduces pulmonary vascular
resistance.10 However, nitric oxide has a high selectivity
for the pulmonary circulation, with the potential dis-
advantage of increasing pulmonary capillary wedge pres-
sure in patients with systemic ventricular dysfunction.11
Further, in a previous study, nitric oxide failed to increase
cardiac output (CO) in Fontan patients.10 Sildenafil has
been shown to be as effective a pulmonary vasodilator as
inhaled nitric oxide in patients with pulmonary arterial
hypertension, and in children with CHD.1–3,10 Sildenafil
was also recently shown to be able to increase exercise Health, Inc. All rights reserved.
Control group (n¼17) P value
1 0.58
37868 0.29
6410 0.48
14.71.4 0.0001
0.230.03 0.0043
97.62.1 0.31
1770310 0.0003
83.814.7 0.0045
7.71.3 0.0004
0.80.3 0.30
277 0.0005
21090 0.51
23.36 0.0004
10916 0.0001
systemic blood pressure; SpO2, peripheral oxygen saturation.
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hypertension or acquired heart failure patients.12 The
successful use of pulmonary vasodilators has been
reported in postoperative Fontan patients. Yoshimura
et al.13 have reported the significant benefit of nitric oxide
to central venous pressure and transpulmonary gradient
after Fontan-type operations. To prevent the rebound
effects of inhaled nitric oxide, epoprostenol has also been
used in combination for postoperative patients.14 Several
cases of successful treatment with sildenafil have been
reported in patients with findings of protein-losing
enteropathy and plastic bronchitis.15–17
As experience with sildenafil in cardiac surgery is limited
to few studies, the optimal dose has not been established
yet.
In our study, a low dose (0.35mg/kg) of oral sildenafil
was used after Fontan operation without concomitant
pulmonary vasodilators. No complications related to
the use of sildenafil were noted in our series, but
a randomized, double-blind, placebo-controlled, dose-
ranging study of oral sildenafil has shown that high doses
increase adverse events.18
Many variables after surgery were better in the sildenafil
group without complications related to sildenafil therapy.
Particularly, hemodynamic parameters showed a better
condition with a lowermPAP, a better mPAP/mSBP ratio,
and a lower inotropic score, used as an independent
predictor of clinical outcome in infants after cardiac
surgery.19 Also the total and relative drainage losses
were lower in the sildenafil group with lower persistence
time of chest drainage. There were no exclusion criteria,
but in this period we did not have patients with PVR
more than 2.5 Wood units. Certainly, there will be some
high-risk Fontan patients who could benefit from having
sildenafil therapy.
To our knowledge, this is the first case series of patients
undergoing Fontan operation, who had been treated with
sildenafil in the postoperative period and compared with
a control group.
Study limitations
The retrospective design of this study on a small number
of patients naturally impedes inference of possible
causalities. A historical control group is utilized, but
alterations and improvements in the surgical procedures
and perioperative environment between the two periods
can obviously not be ruled out. Accordingly, a large
multicenter, randomized controlled trial with established
doses is warranted to validate the efficacy of sildenafil
in comparison with placebo or other vasodilators drugs. Copyright © 2015 Wolters KluweIn summary, this initial experience suggests that oral
sildenafil can be an effective agent to approach the
Fontan circulation with a positive effect in postoperative
management, but further studies, larger and randomized,
are necessary to determine the efficacy, safety and
optimal dosing in children following cardiac surgery.
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